Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure

PLoS One. 2015 Apr 13;10(4):e0122360. doi: 10.1371/journal.pone.0122360. eCollection 2015.

Abstract

Aims: Galectin-3 (Gal-3) and carbohydrate antigen 125 (CA125) have emerged as robust prognostic biomarkers in heart failure. Experimental data have also suggested a potential molecular interaction between CA125 and Gal-3; however, the biological and clinical relevance of this interaction is still uncertain. We sought to evaluate, in patients admitted for acute heart failure, the association between plasma Gal-3 with all-cause mortality and the risk for rehospitalizations among high and low levels of CA125.

Methods and results: We included 264 consecutive patients admitted for acute heart failure to the Cardiology Department in a third-level center. Both biomarkers were measured on admission. Negative binomial and Cox regression models were used to evaluate the prognostic effect of the interaction between Gal-3 and CA125 (dichotomized by its median) with hospital readmission and all-cause mortality, respectively. During a median follow-up of 2 years (IQR = 1-2.8), 108 (40.9%) patients deaths and 365 rehospitalizations in 171 (69.5%) patients were registered. In a multivariable setting, the effect of Gal-3 on mortality and rehospitalization was differentially mediated by CA125 (p = 0.007 and p<0.001, respectively). Indeed, in patients with CA125 above median (>67 U/ml), values across the continuum of Gal-3 showed a positive and almost linear relationship with either the risk of death or rehospitalization. Conversely, when CA125 was below median (≤67 U/ml), Gal-3 lacked any prognostic effect on both endpoints.

Conclusion: In patients with acute heart failure, Gal-3 was strongly associated with higher risk of long-term mortality and repeated rehospitalizations, but only in those patients exhibiting higher values of CA125 (above 67 U/ml).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers / blood*
  • Blood Proteins
  • CA-125 Antigen / blood*
  • Female
  • Follow-Up Studies
  • Galectin 3 / blood*
  • Galectins
  • Heart Failure / blood*
  • Heart Failure / mortality
  • Heart Failure / pathology
  • Humans
  • Male
  • Middle Aged
  • Patient Readmission
  • Prognosis
  • Proportional Hazards Models
  • Risk Factors

Substances

  • Biomarkers
  • Blood Proteins
  • CA-125 Antigen
  • Galectin 3
  • Galectins
  • LGALS3 protein, human

Grants and funding

This work was supported in part by grants from Convocatoria Investigación Clínica Independiente Ministerio de Económica y Competitividad (Cofinanciado FEDER) Referencia EC10-108. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.